Unicycive Therapeutics’ (UNCY) “Speculative Buy” Rating Reiterated at Benchmark

Benchmark reiterated their speculative buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $3.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.50 target price on shares of Unicycive Therapeutics in a research report on Tuesday, November 12th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ UNCY opened at $0.55 on Friday. Unicycive Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.82. The company has a market cap of $57.36 million, a price-to-earnings ratio of -0.57 and a beta of 2.29. The business’s 50 day moving average price is $0.45 and its 200-day moving average price is $0.52.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UNCY. Bleakley Financial Group LLC bought a new position in shares of Unicycive Therapeutics during the third quarter valued at approximately $33,000. Virtu Financial LLC bought a new stake in Unicycive Therapeutics during the 1st quarter valued at $36,000. BVF Inc. IL increased its holdings in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after acquiring an additional 1,493,462 shares during the period. XTX Topco Ltd bought a new position in shares of Unicycive Therapeutics in the 3rd quarter worth $29,000. Finally, Walleye Capital LLC purchased a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth $2,040,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.